The FDA has approved Genentech’s Susvimo (ranibizumab) to treat patients with diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,